cell type: OCI-Ly7 cell line
treatment: treated with 2uM GSK669 for 7 days
cell type: OCI-Ly7 cell line
treatment: treated with 2uM GSK343 for 7 days
cell type: Farage cell line
treatment: treated with 2uM GSK343 for 7 days
cell type: Farage cell line
treatment: treated with 2uM GSK343 for 7 days
cell type: Farage cell line
treatment: treated with 2uM GSK669 for 7 days
cell type: Farage cell line
treatment: treated with 2uM GSK669 for 7 days
cell type: SUDHL5 cell line
treatment: treated with 2uM GSK343 for 7 days
cell type: SUDHL5 cell line
treatment: treated with 2uM GSK343 for 7 days
cell type: OCI-Ly1 cell line
treatment: treated with 2uM GSK343 for 7 days
cell type: OCI-Ly1 cell line
treatment: treated with 2uM GSK343 for 7 days
cell type: SUDHL5 cell line
treatment: treated with 2uM GSK669 for 7 days
cell type: SUDHL5 cell line
treatment: treated with 2uM GSK669 for 7 days
cell type: OCI-Ly1 cell line
treatment: treated with 2uM GSK669 for 7 days
cell type: OCI-Ly1 cell line
treatment: treated with 2uM GSK669 for 7 days
cell type: WSUDLCL2 cell line
treatment: treated with 2uM GSK343 for 7 days
cell type: Pfeiffer cell line
treatment: treated with 2uM GSK343 for 7 days
cell type: Pfeiffer cell line
treatment: treated with 2uM GSK343 for 7 days
cell type: WSUDLCL2 cell line
treatment: treated with 2uM GSK669 for 7 days
cell type: OCI-Ly7 cell line
treatment: transduced with anti-EZH2 shRNA #2 for EZH2 for 7 days
cell type: Pfeiffer cell line
treatment: treated with 2uM GSK669 for 7 days
cell type: Pfeiffer cell line
treatment: treated with 2uM GSK669 for 7 days
cell type: OCI-Ly7 cell line
treatment: transduced with anti-EZH2 shRNA #3 for EZH2 for 7 days
cell type: OCI-Ly7 cell line
treatment: transuced with control scrambled shRNA for 7 days
cell type: Farage cell line
treatment: transduced with anti-EZH2 shRNA #3 for EZH2 for 7 days
cell type: Farage cell line
treatment: transduced with anti-EZH2 shRNA #2 for EZH2 for 7 days
cell type: Farage cell line
treatment: transduced with control scrambled shRNA for 7 days
cell type: SUDHL5 cell line
treatment: transduced with anti-EZH2 shRNA #2 for EZH2 for 7 days
cell type: SUDHL5 cell line
treatment: transduced with anti-EZH2 shRNA #3 for EZH2 for 7 days
cell type: SUDHL5 cell line
treatment: transuced with control scrambled shRNA for 7 days
cell type: OCI-Ly1 cell line
treatment: transduced with anti-EZH2 shRNA #2 for EZH2 for 7 days
cell type: OCI-Ly1 cell line
treatment: transduced with anti-EZH2 shRNA #3 for EZH2 for 7 days
cell type: OCI-Ly1 cell line
treatment: transuced with control scrambled shRNA for 7 days
cell type: WSUDLCL2 cell line
treatment: transduced with anti-EZH2 shRNA #2 for EZH2 for 7 days
cell type: WSUDLCL2 cell line
treatment: transduced with anti-EZH2 shRNA #3 for EZH2 for 7 days
cell type: WSUDLCL2 cell line
treatment: transuced with control scrambled shRNA for 7 days
cell type: Tonsillar naive B cells
treatment: NA
purification: Cells purified from normal fresh human tonsillectomy specimens by magnetic bead cell separation based on the expression the phenotypic marker IgD
cell type: Tonsillar naive B cells
treatment: NA
purification: Cells purified from normal fresh human tonsillectomy specimens by magnetic bead cell separation based on the expression the phenotypic marker IgD
cell type: Tonsillar naive B cells
treatment: NA
purification: Cells purified from normal fresh human tonsillectomy specimens by magnetic bead cell separation based on the expression the phenotypic marker IgD
cell type: Tonsillar Germinal Center B cells
treatment: NA
purification: Cells purified from normal fresh human tonsillectomy specimens by magnetic bead cell separation based on the expression the phenotypic marker CD77
cell type: Tonsillar naive B cells
treatment: NA
purification: Cells purified from normal fresh human tonsillectomy specimens by magnetic bead cell separation based on the expression the phenotypic marker IgD
cell type: Tonsillar Germinal Center B cells
treatment: NA
purification: Cells purified from normal fresh human tonsillectomy specimens by magnetic bead cell separation based on the expression the phenotypic marker CD77
cell type: Tonsillar Germinal Center B cells
treatment: NA
purification: Cells purified from normal fresh human tonsillectomy specimens by magnetic bead cell separation based on the expression the phenotypic marker CD77
cell type: Tonsillar Germinal Center B cells
treatment: NA
purification: Cells purified from normal fresh human tonsillectomy specimens by magnetic bead cell separation based on the expression the phenotypic marker CD77